Laboratory And Molecular-Genetic Markers Of The Progression Of Non-Alcoholic Fatty Liver Disease (literature review and own data)

2021 ◽  
Vol 03 (03) ◽  
pp. 75-82
Author(s):  
Hamrayev A.A. ◽  
◽  
Yuldasheva D.H. ◽  
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Molecular Genetic ◽  
Elevated Serum ◽  
Serum Triglyceride ◽  
Alcoholic Fatty Liver ◽  
Hereditary Factors ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases in hepatology. First of all, this is associated with a high risk of progression of NAFLD with the development of non-alcoholic steatohepatitis (NASH), liver failure, and hepatocellular carcinoma. Epidemiological and genetic studies have shown the relationship between the morphological stage of NAFLD and hereditary factors. The article provides a review of the literature on the cytokines, MBOAT7 and GCKR genes. Also, a variant of the MBOAT7 and GCKR gene is associated with a high risk of fibrosis in patients with NAFLD and elevated serum triglyceride levels.

scholarly journals Clinical, laboratory and molecular-genetic markers of the progression of non-alcoholic fatty liver disease (literature review and own data)

2021 ◽  
Vol 2 (2/S) ◽  
pp. 399-406
Author(s):  
A.A. Хamrayev ◽  
D.H Yuldasheva
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Clinical Laboratory ◽  
Molecular Genetic ◽  
Elevated Serum ◽  
Serum Triglyceride ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases in hepatology. First of all, this is associated with a high risk of progression of NAFLD with the development of non-alcoholic steatohepatitis (NASH), liver failure, and hepatocellular carcinoma. Epidemiological and genetic studies have shown the relationship between the morphological stage of NAFLD and hereditary factors. The article provides a review of the literature on the cytokines, MBOAT7 and GCKR genes. Also, a variant of the MBOAT7 and GCKR gene is associated with a high risk of fibrosis in patients with NAFLD and elevated serum triglyceride levels.

Have we learnt all from Improve-It? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non- alcoholic fatty liver disease)

2020 ◽  
Vol 18 ◽  
Author(s):  
Zlatko Fras ◽  
Dimitri P. Mikhailidis
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
High Risk ◽  
Kidney Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Risk Patients ◽  
Very High ◽  
Alcoholic Fatty Liver Disease

: IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clini- cal trial (18,144 patients) that evaluated the efficacy of the combination of ezetimibe with simvastatin vs simvastatin mono- therapy in patients with acute coronary syndrome (ACS) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016). Therefore, for very high cardiovascular risk patients “even lower is even better” regarding LDL-C, independently of the LDL-C reducing strategy. These findings confirm ezetimibe as an option to treat very-high-risk patients who cannot achieve LDL-C targets with statin monotherapy. Additional analyses of the IMPROVE-IT (both prespecified and post-hoc) include specific very-high-risk subgroups of patients (those with previous acute events and/or coronary revascularization, older than 75 years, as well as patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease). The data from IMPROVE-IT also provide reassurance regarding longer-term safety and efficacy of the intensification of li- pid-lowering therapy in very-high-risk patients resulting in very low LDL-C levels. We comment on the results of several (sub) analyses of IMPROVE-IT.

scholarly journals Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2316
Author(s):  
Suguru Ikeda ◽  
Takaaki Sugihara ◽  
Takuya Kihara ◽  
Yukako Matsuki ◽  
Takakazu Nagahara ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Gamma Glutamyl Transferase ◽  
Alcoholic Fatty Liver ◽  
Clinical Criteria ◽  
One Year ◽  
Glutamyl Transferase ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome. No standard pharmacological treatment has yet been established. We retrospectively evaluated the efficacy of pemafibrate in 16 NAFLD patients (11 men and 5 women; median age, 59 years; range, 27–81 years) who had taken pemafibrate for at least one year. They were all diagnosed with fatty liver according to imaging and clinical criteria. They were administered pemafibrate from October 2018 to October 2021 (median, 94 weeks; range, 56–157 weeks). Serum triglyceride was significantly decreased by −41.9% (342.3 ± 54.0 to 198.9 ± 20.4 mg/dL, p < 0.001). Aspartate aminotransferase (AST), alanine aminotransferase, and gamma-glutamyl transferase levels significantly decreased by −42.1% (49.6 ± 7.0 to 28.7 ± 3.4 U/L, p < 0.001), −57.1% (65.1 ± 10.8 to 27.9 ± 3.7 U/L, p < 0.001), and −43.2% (68.9 ± 10.9 to 39.1 ± 5.3 U/L, p < 0.05), respectively. The AST to platelet ratio (APRI) (0.8 ± 0.1 to 0.4 ± 0.1, p < 0.001) and fibrosis based on four factors (FIB-4) index (1.8 ± 0.3 to 1.4 ± 0.2, p < 0.05) also significantly decreased. Liver attenuation (39.1 ± 1.2 to 57.8 ± 2.7 HU, p = 0.028) and liver/spleen ratio (0.76 ± 0.04 to 1.18 ± 0.02, p = 0.012) significantly improved in three patients, as assessed by computed tomography. In conclusion, pemafibrate significantly improves serum triglyceride levels, liver function, FIB-4 index, APRI, and fatty liver in NAFLD patients with hypertriglyceridemia.

A Correlation Study Between Non-alcoholic Fatty Liver Disease and Serum Triglyceride Level After an Oral Fat Tolerance Test

2021 ◽  
Author(s):  
Xiaoyu Hou ◽  
Yunpeng Guan ◽  
Yong Tang ◽  
An Song ◽  
Jiajun Zhao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Serum Triglyceride Level ◽  
Peak Time ◽  
Alcoholic Fatty Liver ◽  
Postprandial Triglyceride ◽  
Healthy Participants ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. High postprandial serum lipid concentrations have been reported in patients with metabolic syndrome. Meanwhile, postprandial triglyceride (TG) was found to be a potential replacement when fasting TG is not available. We aimed to investigate the relationship between postprandial TG concentration during oral fat tolerance testing (OFTT) and NAFLD. Methods : A total of 472 Chinese adults, aged 25 to 65 years enrolled in this study. All the participants underwent OFTT. Serum triglyceride and other lipid concentrations were measured, and their relationships with NAFLD were analyzed. Results: Of the 472 participants, 155 were diagnosed with NAFLD. The fasting and postprandial TG concentrations of the participants with NAFLD were higher than those of healthy participants (P<0.05). The TG concentrations of the healthy participants peaked 4 h postprandially, whereas those of the participants with NAFLD peaked 6 h postprandially and had higher peak values. Postprandial triglyceride concentration showed significant association with higher risk of NAFLD.Conclusions: Higher postprandial TG concentration is positively related to higher risk of NAFLD, and postprandial TG concnetrations of NAFLD patients were higher than healthy individuals with a delayed peak time. Hence, 4h postprandial TG maybe a potential indicator for NAFLD.Trial registration number: ChiCTR1800019514

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

2020 ◽  
Vol 52 (3) ◽  
pp. 513-526 ◽  
Author(s):  
Zobair M. Younossi ◽  
Kathleen E. Corey ◽  
Naim Alkhouri ◽  
Mazen Noureddin ◽  
Ira Jacobson ◽  
...  
Keyword(s):  
Primary Care ◽  
Liver Disease ◽  
High Risk ◽  
Fatty Liver ◽  
Clinical Assessment ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
High Risk Patients ◽  
Risk Patients ◽  
Alcoholic Fatty Liver Disease

scholarly journals Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

2015 ◽  
Vol 47 (12) ◽  
pp. 997-1006 ◽  
Author(s):  
Amedeo Lonardo ◽  
Stefano Bellentani ◽  
Curtis K. Argo ◽  
Stefano Ballestri ◽  
Christopher D. Byrne ◽  
...  
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Risk Groups ◽  
Alcoholic Fatty Liver ◽  
Disease Focus ◽  
Alcoholic Fatty Liver Disease

scholarly journals Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

2021 ◽  
Author(s):  
Rosa Lombardi ◽  
Giuseppina Pisano ◽  
Silvia Fargion ◽  
Anna Ludovica Fracanzani
Keyword(s):  
Metabolic Syndrome ◽  
Liver Transplantation ◽  
Liver Disease ◽  
High Risk ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Patients submitted to liver transplantation (LT) are exposed to high risk of cardiovascular (CV) complications which are the main determinants of both short-term and long-term morbidity and mortality in LT. Non-alcoholic fatty liver disease (NAFLD) is a very frequent condition in general population and is associated with a high risk of cardiovascular disease (CVD) which represents the first cause of death of these patients. NAFLD is predicted to become the first indication to LT and nowadays is also frequently detected in patients submitted to LT for other indications. Thus, the risk of CVD in patients submitted to LT is forecasted to increase in the next years. In this review the extent of CV involvement in patients submitted to LT and the role of NAFLD, either recurring after transplantation or as de novo presentation, in increasing CV risk is analysed. The risk of developing metabolic alterations, including diabetes, hypertension, dyslipidemia and weight gain, all manifestations of metabolic syndrome, occurring in the first months after LT, is depicted. The different presentations of cardiac involvement, represented by early atherosclerosis, coronary artery disease, heart failure and arrhythmias in patients with NAFLD submitted to LT is described. In addition, the tools to detect cardiac alterations either before or after LT is reported providing the possibility for an early diagnosis of CVD and an early therapy able to reduce morbidity and mortality for these diseases. The need for long-term concerted multidisciplinary activity with dietary counseling and exercise combined with drug treatment of all manifestations of metabolic syndrome is emphasized.

Sign in / Sign up

Export Citation Format

Share Document